Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
124.37
+1.87 (1.53%)
At close: Oct 20, 2026, 4:00 PM EDT
123.37
-1.00 (-0.80%)
Pre-market: Oct 21, 2026, 9:05 AM EDT
Halozyme Therapeutics Market Cap
Halozyme Therapeutics has a market cap or net worth of $14.12 billion as of October 20, 2026. It is the 1,608th most valuable company in the world and the 601st biggest in the United States. Its market cap has increased by 80.04% in one year.
Market Cap
14.12B
Enterprise Value
16.06B
1-Year Change
80.04%
Global Rank
Country Rank
#601 United States
Category
ChartMarket Cap Chart
Since March 16, 2004, Halozyme Therapeutics's market cap has increased from $8.10M to $14.12B, an increase of 174,168.47%. That is a compound annual growth rate of 39.11%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 20, 2026 | 14.12B | 78.36% |
| Dec 31, 2025 | 7.91B | 30.11% |
| Dec 31, 2024 | 6.08B | 24.59% |
| Dec 29, 2023 | 4.88B | -36.54% |
| Dec 30, 2022 | 7.69B | 35.91% |
| Dec 31, 2021 | 5.66B | -1.95% |
| Dec 31, 2020 | 5.77B | 122.23% |
| Dec 31, 2019 | 2.60B | 22.85% |
| Dec 31, 2018 | 2.11B | -26.67% |
| Dec 29, 2017 | 2.88B | 125.43% |
| Dec 30, 2016 | 1.28B | -42.33% |
| Dec 31, 2015 | 2.22B | 83.35% |
| Dec 31, 2014 | 1.21B | -29.21% |
| Dec 31, 2013 | 1.71B | 126.01% |
| Dec 31, 2012 | 756.30M | -23.30% |
| Dec 30, 2011 | 986.10M | 23.98% |
| Dec 31, 2010 | 795.40M | 47.84% |
| Dec 31, 2009 | 538.00M | 17.96% |
| Dec 31, 2008 | 456.10M | -17.36% |
| Dec 31, 2007 | 551.90M | 6.38% |
| Dec 29, 2006 | 518.80M | 469.48% |
| Dec 30, 2005 | 91.10M | -13.07% |
| Dec 31, 2004 | 104.80M | 1,193.83% |
| Mar 16, 2004 | 8.10M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Exelixis | 15.53B |
| Ascendis Pharma | 15.10B |
| Jazz Pharmaceuticals | 13.53B |
| BridgeBio Pharma | 13.28B |
| Summit Therapeutics | 12.45B |
| Corcept Therapeutics | 12.12B |
| Bio-Techne | 11.37B |
| BioMarin Pharmaceutical | 10.58B |